Walleye Capital’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,200
| Closed | -$129K | – | 4718 |
|
|
2026
Q1 | $129K | Sell |
3,200
-4,300
| -57% | -$92.7K | ﹤0.01% | 3562 |
|
|
2025
Q4 | $188K | Buy |
7,500
+2,900
| +63% | +$68K | ﹤0.01% | 3565 |
|
|
2025
Q3 | $104K | Sell |
4,600
-2,900
| -39% | -$67.6K | ﹤0.01% | 3701 |
|
|
2025
Q2 | $130K | Buy |
7,500
+7,000
| +1,400% | +$130K | ﹤0.01% | 3641 |
|
|
2025
Q1 | $10.9K | Sell |
500
-2,300
| -82% | -$63.5K | ﹤0.01% | 4059 |
|
|
2024
Q4 | $89.3K | Buy |
2,800
+2,600
| +1,300% | +$78.2K | ﹤0.01% | 4182 |
|
|
2024
Q3 | $5.77K | Sell |
200
-1,600
| -89% | -$59.3K | ﹤0.01% | 4984 |
|
|
2024
Q2 | $69K | Sell |
1,800
-25,400
| -93% | -$1.15M | ﹤0.01% | 4845 |
|
|
2024
Q1 | $1.6M | Buy |
27,200
+10,000
| +58% | +$637K | ﹤0.01% | 2161 |
|
|
2023
Q4 | $1.03M | Sell |
17,200
-100
| -0.6% | -$5.07K | ﹤0.01% | 2314 |
|
|
2023
Q3 | $658K | Buy |
17,300
+8,900
| +106% | +$391K | ﹤0.01% | 2599 |
|
|
2023
Q2 | $765K | Buy |
8,400
+6,100
| +265% | +$526K | ﹤0.01% | 2073 |
|
|
2023
Q1 | $152K | Sell |
2,300
-6,800
| -75% | -$392K | ﹤0.01% | 2679 |
|
|
2022
Q4 | $471K | Buy |
9,100
+7,800
| +600% | +$414K | 0.01% | 1492 |
|
|
2022
Q3 | $89K | Buy |
+1,300
| New | +$76.9K | ﹤0.01% | 2462 |
|
|
2020
Q2 | – | Sell |
-14,600
| Closed | -$391K | – | 609 |
|
|
2020
Q1 | $391K | Buy |
+14,600
| New | +$518K | 0.09% | 275 |
|
Other funds holding APLS
Walleye Capital's APLS Position: Q2 2026 in Review
Walleye Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 3,290 shares — an estimated $132K sold.
Walleye Capital first reported a position in APLS in Q4 2021 and held it in 15 quarters. The position peaked at $12.6M in Q4 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Walleye Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Walleye Capital sold 3,290 Apellis Pharmaceuticals shares in Q2 2026, an estimated $132K.
- Walleye Capital first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 15 quarters.
- Walleye Capital's Apellis Pharmaceuticals position peaked at $12.6M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.